{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:36:34Z","timestamp":1768030594056,"version":"3.49.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Breast cancer, prostate cancer, kidney cancer, multiple myeloma, osteoporosis, and the use of antiresorptive and antiangiogenic drugs are risk factors for osteonecrosis of the jaw (ONJ). Denosumab is a Receptor activator of nuclear factor kappa-\u0392 ligand antagonist monoclonal antibody that inhibits the differentiation and function of osteoclasts over osteoblasts. It is an antiresorptive drug used to reduce the development of skeletal events in solid cancers. Denosumab-induced ONJ is a rare condition, occurring in 0% to 4.6% of cases. In this case, the findings of 68Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET)\/Computed Tomography (CT) and 18F Fluorodeoxyglucose (FDG) PET\/CT are presented in a man with metastatic castration-resistant prostate cancer who developed ONJ due to denosumab use.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005751","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T01:00:44Z","timestamp":1740963644000},"page":"e568-e569","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["68Ga PSMA PET\/CT and 18F FDG PET\/CT Findings in Osteonecrosis of the Jaw Induced by Denosumab"],"prefix":"10.1097","volume":"50","author":[{"given":"Zehranur","family":"Tosuno\u011flu","sequence":"first","affiliation":[{"name":"Istanbul Training and Research Hospital, Clinic of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ksel","family":"Al\u00e7in","sequence":"additional","affiliation":[{"name":"Istanbul Training and Research Hospital, Clinic of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elife","family":"Akg\u00fcn","sequence":"additional","affiliation":[{"name":"Istanbul Training and Research Hospital, Clinic of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lkay","family":"G\u00fclt\u00fcrk","sequence":"additional","affiliation":[{"name":"Istanbul Training and Research Hospital, Clinic of Medical Oncology, University of Health Sciences, \u0130stanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-8883","authenticated-orcid":false,"given":"Esra","family":"Arslan","sequence":"additional","affiliation":[{"name":"Istanbul Training and Research Hospital, Clinic of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.1038\/s41598-024-59500-x","article-title":"Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw","volume":"14","author":"Shin","year":"2024","journal-title":"Sci Rep"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","article-title":"Osteonecrosis of the jaw: who gets it, and why?","volume":"44","author":"Reid","year":"2009","journal-title":"Bone"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R6-20250731","first-page":"774","article-title":"High-dose denosumab (Xgeva) associated medication-related osteonecrosis of the jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients","volume":"32","author":"Moon","year":"2024","journal-title":"Support Care Cancer"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00204-023-03653-7","article-title":"Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies","volume":"98","author":"Jiang","year":"2024","journal-title":"Arch Toxicol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"20200417","DOI":"10.1259\/dmfr.20200417.c","article-title":"Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw?","volume":"51","author":"Wongratwanich","year":"2022","journal-title":"Dentomaxillofac Radiol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000004970","article-title":"A Comparison of 18 F-FDG PET\/CT and 68 Ga-PSMA PET\/CT in detecting osteonecrosis of the jaw in a patient with prostate cancer","volume":"49","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:44Z","timestamp":1753938044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005751","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}